Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety Study: A Multi-Center, Double-Masked Phase 3 Safety Study Evaluation of the Long-Term Safety of LNZ101 in Presbyopic Subjects

NCT05753189 is registered in ClinicalTrials.gov with LENZ Therapeutics, Inc as lead sponsor.

NCT NCT05753189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05753189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety Study: A Multi-Center, Double-Masked Phase 3 Safety Study Evaluation of the Long-Term Safety of LNZ101 in Presbyopic Subjects
Lead sponsor
LENZ Therapeutics, Inc
Phase
Phase 3
Overall status
Completed
Start date
February 21, 2023
Completion date
February 9, 2024
Enrollment
362 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

eye diseases, near vision, presbyopia, refractive error